Loading...
•
Dec 31, 2020
Fate Therapeutics Q4 2020 Earnings Report
Fate Therapeutics reported fourth quarter 2020 financial results and highlighted operational progress.
Key Takeaways
Fate Therapeutics reported a revenue of $15.9 million for the fourth quarter of 2020, derived from collaborations with Janssen and Ono Pharmaceutical. The company's cash, cash equivalents, and investments totaled $482.9 million as of December 31, 2020. Research and development expenses were $39.0 million, and general and administrative expenses were $10.3 million for the quarter.
Positive interim data reported from FT516 Phase 1 study in relapsed / refractory BCL, with objective responses achieved in 3 of 4 patients in dose cohorts 2 and 3.
Clinical activity of FT596 as monotherapy demonstrated in refractory DLBCL, with a partial response achieved and deepening of response upon FT596 retreatment in a patient in dose cohort 1.
IND application allowed by FDA for FT576, the first-ever cell therapy engineered with four functional anti-tumor modalities, for relapsed / refractory multiple myeloma.
Over $900 million in cash & short-term investments following January 2021 public offering.
Fate Therapeutics
Fate Therapeutics
Fate Therapeutics Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com